Surgical Resection Improves Survival in BCLC Stage C Hepatocellular Carcinoma
the Cancer Therapy Advisor take:
Surgical resection provides significantly better long-term survival compared to transarterial chemoembolization (TACE) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC), according to a study published in the Journal of Surgical Oncology.
Taiwanese researchers led by Po-Hong Lui, MD, of the Taipei Veterans General Hospital examined patients being treated for their HCC, 264 with surgical resection and 389 with TACE. Among these patients, 163 matched pairs were identified from each arm by propensity score analysis in order to compare long-term survival.
They found that the group that underwent surgical resection had better liver function reserve than the TACE group, and demonstrated better long-term survival. After matched propensity modeling, baseline characteristics were similar between the two groups.
In addition, with Cox proportional modeling, patients who underwent TACE had an increased risk of mortality compared to those who underwent surgical resection.
“Multidisciplinary approaches for these patients and further amendments to the BCLC classification scheme are required,” the authors concluded.
Surgical resection provides better survival compared to transarterial chemoembolization in hepatocellular carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML